All comparisons
Comparison · peptides
BPC-157 vs TB-500
BPC-157 supports GI, tendon, and ligament repair. TB-500 supports muscle, broader connective tissue, and vascular repair. They are often used in combined protocols under provider review.
Reviewed by Dr. Laura PurdyMay 29, 2026
Attribute
BPC-157
TB-500 (thymosin beta-4)
Primary tissues
Tendon, ligament, GI
Muscle, vasculature, broader connective
Route
Subq or oral
Subq
Onset
Days to weeks
Weeks
Common protocol length
4–8 weeks
4–8 weeks
Combined use
Common
Common
Choose BPC-157
BPC-157 is appropriate for tendon, ligament, or GI repair contexts.
Choose TB-500 (thymosin beta-4)
TB-500 is appropriate for broader muscle and connective tissue repair contexts.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Can they be combined?
Yes — combined protocols are common under provider review.
Are they FDA-approved?
No — both remain research/compounded peptides.
Next step
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment